Browsing Tag
Neumora Therapeutics
3 posts
Neumora (NASDAQ: NMRA) to begin Phase 1 trial of oral NLRP3 obesity pill in early 2026: Can it rival GLP-1 pills?
Find out how Neumora Therapeutics’ oral obesity candidate NMRA‑215 is advancing to human trials. Could it reshape the future of weight loss therapies?
MapLight Therapeutics prices $250m Nasdaq IPO at $17 a share as biotech listings rebound
Find out how MapLight Therapeutics’ $250 million Nasdaq IPO is reigniting biotech investor sentiment and funding its next wave of CNS drug trials.
Neumora Therapeutics’ KOASTAL-1 study of navacaprant for MDD falls short on primary endpoint
Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company specialising in neuroscience, has announced results from the KOASTAL-1…